C.M. Bidwell & Associates’s Sarepta Therapeutics SRPT Stock Holding History

C.M. Bidwell & Associates’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.18K	Hold	177	–	–	﹤0.01%	381
2026 Q1	$3.85K	Hold	177	–	–	﹤0.01%	355
2025 Q4	$3.81K	Hold	177	–	–	﹤0.01%	360
2025 Q3	$3.41K	Hold	177	–	–	﹤0.01%	373
2025 Q2	$3.03K	Buy	+177	New	+$7.55K	﹤0.01%	366
2024 Q3	–	Sell	-4	Closed	-$632	–	542
2024 Q2	$632	Hold	4	–	–	﹤0.01%	429
2024 Q1	$518	Hold	4	–	–	﹤0.01%	440
2023 Q4	$386	Sell	4 -1,549	-100%	-$149K	﹤0.01%	461
2023 Q3	$188K	Sell	1,553 -28	-2%	-$3.17K	0.14%	122
2023 Q2	$181K	Hold	1,581	–	–	0.13%	133
2023 Q1	$218K	Sell	1,581 -97	-6%	-$12.6K	0.17%	106
2022 Q4	$217K	Hold	1,678	–	–	0.17%	114
2022 Q3	$185K	Buy	1,678 +1,058	+171%	+$107K	0.15%	122
2022 Q2	$46K	Buy	620 +590	+1,967%	+$43.4K	0.04%	283
2022 Q1	$2K	Sell	30 -1,615	-98%	-$124K	﹤0.01%	483
2021 Q4	$148K	Buy	+1,645	New	+$141K	0.09%	205

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

C.M. Bidwell & Associates's SRPT Position: Q2 2026 in Review

C.M. Bidwell & Associates held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 177 shares worth $3.18K. The position accounts for ﹤0.01% of the portfolio, ranked #381.

C.M. Bidwell & Associates first reported a position in SRPT in Q4 2021 and has held it in 16 quarters since. The position peaked at $218K in Q1 2023. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

C.M. Bidwell & Associates held 177 shares of Sarepta Therapeutics worth $3.18K as of Q2 2026.
C.M. Bidwell & Associates left its Sarepta Therapeutics share count unchanged in Q2 2026.
Sarepta Therapeutics made up ﹤0.01% of C.M. Bidwell & Associates's portfolio in Q2 2026, its #381 holding.
C.M. Bidwell & Associates first reported a position in Sarepta Therapeutics in Q4 2021 and has held it in 16 quarters since.
C.M. Bidwell & Associates's Sarepta Therapeutics position peaked at $218K in Q1 2023.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.